Surletro
Surletro (Letrozole 2.5 mg Tablet) is an ovulation induction therapy specially formulated for women with PCOS, anovulation, and infertility management. It is widely recommended as a first-line treatment option for improving ovulation and increasing pregnancy outcomes in assisted reproductive care.
Clinical Insights:-
PCOS affects a significant percentage of reproductive-age women, and anovulation remains one of the leading causes of infertility. Clinical practice supports Letrozole as a preferred ovulation induction therapy, especially in women showing clomiphene resistance or irregular ovulation patterns.
Key Benefits
- Supports effective ovulation induction
- Improves pregnancy & live birth outcomes in PCOS
- Endometrium-friendly formulation
- Lower risk of OHSS & multiple gestation
- Well tolerated with minimal side effects
- Recommended in clomiphene-resistant infertility
- Used in IVF ovulation induction protocols
Why Choose Surletro?
Indications
Surletro is indicated in women with:
- PCOS & anovulation
- Clomiphene-resistant infertility
- Ovulation disorders
- Metabolic infertility
- Unexplained infertility (IUI cycles)
- Assisted reproductive protocols
Dosage Information
| Condition | Dose | Duration |
|---|---|---|
| PCOS Ovulation Induction | 2.5 mg OD | Day 2–6 Cycle |
| Unexplained Infertility (IUI Cycles) | 5 mg OD | Day 2–6 Cycle |
Safety Information
- Use only under medical supervision
- Store in a cool & dry place
- Keep away from children
- Do not exceed prescribed dosage
FAQs
What is Surletro used for?
Surletro is used for ovulation induction in women with PCOS, anovulation, and infertility management.
Is Surletro useful in IVF protocols?
Yes, it is commonly used in IVF and assisted reproduction protocols for ovulation support.
What makes Surletro different?
Surletro provides effective ovulation induction with better endometrial support and lower risk of multiple gestation & OHSS.
